According to *The Wall Street Journal*, citing people familiar with the matter, British pharmaceutical giant AstraZeneca made an acquisition offer of $124 per share, totaling approximately $10 billion, to biopharmaceutical company Rhythm Pharmaceuticals last month, aimed at expanding its rare disease treatment portfolio.